Edition:
India

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

6.14USD
15 Nov 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.14
Open
$6.22
Day's High
$6.22
Day's Low
$6.03
Volume
114,138
Avg. Vol
206,919
52-wk High
$6.71
52-wk Low
$1.62

Latest Key Developments (Source: Significant Developments)

Ardelyx Reports Q3 Loss Per Share Of $0.37
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 LOSS PER SHARE $0.37.Q3 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, ARDELYX HAD TOTAL CAPITAL RESOURCES INCLUDING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $103.5 MILLION.  Full Article

Ardelyx Inc - Updated Its Progress And Projections With Respect To Its Ongoing Clinical Trials For Its Lead Compound Tenapanor
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Ardelyx Inc ::ARDELYX INC - ON JUNE 5, UPDATED ITS PROGRESS AND PROJECTIONS WITH RESPECT TO ITS ONGOING CLINICAL TRIALS FOR ITS LEAD COMPOUND TENAPANOR.ARDELYX INC - CURRENTLY EXPECTS TO ANNOUNCE DATA IN Q3 OF 2019 FROM ITS PHASE 3 AMPLIFY CLINICAL TRIAL.ARDELYX INC - UPDATE NARROWED COMPANY'S PREVIOUS PROJECTION THAT IT EXPECTED TO ANNOUNCE SUCH DATA IN SECOND HALF OF 2019.ARDELYX - CO REITERATED ITS PREVIOUSLY ANNOUNCED PROJECTION THAT IT EXPECTS TO ANNOUNCE DATA IN THE FOURTH QUARTER OF 2019 FROM ITS ONGOING PHASE 3 PHREEDOM CLINICAL TRIAL.  Full Article

Ardelyx Qtrly Net Loss Per Common Share $0.42
Wednesday, 8 May 2019 

May 7 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.ARDELYX INC - LICENSING REVENUE FOR QUARTER ENDED MARCH 31, 2019 WAS ZERO VERSUS $2.3 MILLION.ARDELYX INC - NET LOSS FOR QUARTER ENDED MARCH 31, 2019, WAS $26.1 MILLION COMPARED TO A NET LOSS OF $17.0 MILLION.ARDELYX INC - QTRLY NET LOSS PER COMMON SHARE $0.42.  Full Article

Ardelyx Says FDA Accepts Its New Drug Application For Tenapanor
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Ardelyx Inc ::ARDELYX ANNOUNCES FDA ACCEPTANCE OF THE FILING OF ITS NEW DRUG APPLICATION FOR TENAPANOR FOR THE TREATMENT OF PATIENTS WITH IBS-C.  Full Article

Ardelyx Inc QTRLY Loss Per Share $0.39
Thursday, 8 Nov 2018 

Ardelyx Inc ::ARDELYX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.AS OF SEPT 30 CO HAD TOTAL CAPITAL RESOURCES INCLUDING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $186.4 MILLION.ARDELYX - MAINTAINS EXPECTATION THAT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WILL BE SUFFICIENT TO FUND OPERATIONS UNTIL AT LEAST MID-2020.QTRLY LOSS PER SHARE $0.39.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.  Full Article

Ardelyx Submits New Drug Application For IBS-C To FDA
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Ardelyx Inc ::ARDELYX SUBMITS NEW DRUG APPLICATION FOR U.S. MARKETING AUTHORIZATION OF TENAPANOR FOR IBS-C TO U.S. FOOD AND DRUG ADMINISTRATION.ARDELYX SUBMITS NEW DRUG APPLICATION FOR U.S. MARKETING AUTHORIZATION OF TENAPANOR FOR IBS-C TO U.S. FOOD AND DRUG ADMINISTRATION.ARDELYX INC - EXPECTS TO RECEIVE NOTIFICATION OF ACCEPTANCE OF FILING FOR SUBSTANTIVE REVIEW BEFORE END OF YEAR.  Full Article

Ardelyx Announces Proposed Public Offering Of Common Stock
Tuesday, 22 May 2018 

May 21 (Reuters) - Ardelyx Inc ::ARDELYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ARDELYX INC - STARTED UNDERWRITTEN PUBLIC OFFERING OF UP TO $50 MLN OF SHARES OF ITS COMMON STOCK.  Full Article

Ardelyx Reports Qtrly Loss Per Share $0.36
Wednesday, 9 May 2018 

May 8 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.QTRLY LOSS PER SHARE $0.36.  Full Article

Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​
Monday, 19 Mar 2018 

March 19 (Reuters) - Ardelyx Inc ::KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​.KNIGHT THERAPEUTICS - ‍WILL PAY UP TO C$25 MILLION IN TOTAL PAYMENTS INCLUDING AN UPFRONT PAYMENT AND DEVELOPMENT AND SALES MILESTONES.KNIGHT THERAPEUTICS INC - ‍KNIGHT WILL HAVE EXCLUSIVE RIGHTS TO MARKET AND SELL TENAPANOR IN CANADA​.  Full Article

Ardelyx Reports Qtrly Earnings Per Share $0.21
Thursday, 15 Mar 2018 

March 14 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS.ARDELYX INC - QTRLY EARNINGS PER SHARE $0.21.  Full Article